Literature DB >> 168914

High affinity oestradiol receptors and the activity of glucose-6-phosphate dehydrogenase and lactose synthetase in mammary carcinomata of postmenopausal women.

J L Daehnfeldt, M Schülein.   

Abstract

The determination of hormone inducible proteins in endocrine tumours may yield information about the presence of hormone dependent tumour cells. We have estimated the high affinity oestradiol binding capacity in primary mammary carcinomata of 57 postmenopausal patients. Glucose-6-phosphate dehydrogenase and lactose synthetase are known from animal experiments to be hormone inducible. Therefore, in biopsies of sufficient size the activity of glucose-6-phosphate dehydrogenase (47 pateints) and lactose synthetase (23 patients) was also studied. It was found that biopsies with high binding capacity also showed high activities of glucose-6-phosphate dehydrogenase and lactose synthetase A protein (galactosyl transferase). No lactose synthetase B protein (alpha-lactalbumin) has been discovered in the tumours. The present observations may be considered suggestive evidence of a relationship between high oestradiol binding capcity and high activities of the two enzymes on the one hand and hormone dependence of the tumour on the other. However, further clinical studies are required before final conclusions in this respect can be drawn.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 168914      PMCID: PMC2009451          DOI: 10.1038/bjc.1975.81

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Further studies on the properties and assay of glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver.

Authors:  G E GLOCK; P McLEAN
Journal:  Biochem J       Date:  1953-10       Impact factor: 3.857

2.  Endogenously blocked high affinity estradiol receptors in the immature and mature rat uterus.

Authors:  J L Daehnfeldt
Journal:  Proc Soc Exp Biol Med       Date:  1974-05

3.  Studies on certain cytoplasmic enzymes and specific estrogen receptors in human breast cancer and in nonmalignant diseases of the breast.

Authors:  R Hilf; J L Wittliff; W D Rector; E D Savlov; T C Hall; R A Orlando
Journal:  Cancer Res       Date:  1973-09       Impact factor: 12.701

4.  Characterization and assay of steroid hormone receptors and steroid-binding serum proteins by agargel electrophoresis at low temperature.

Authors:  R K Wagner
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1972-08

5.  Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans.

Authors:  J L Wittliff; R Hilf; W F Brooks; E D Savlov; T C Hall; R A Orlando
Journal:  Cancer Res       Date:  1972-09       Impact factor: 12.701

6.  Estrogen receptors in human breast cancer.

Authors:  G Leclercq; J C Heuson; R Schoenfeld; W H Mattheiem; H J Tagnon
Journal:  Eur J Cancer       Date:  1973-09       Impact factor: 9.162

7.  Enzyme patterns of glucose catabolism in hormone-dependent and -independent mammary tumours of GR mice.

Authors:  P Briand; J L Daehnfeldt
Journal:  Eur J Cancer       Date:  1973-10       Impact factor: 9.162

8.  Lactose synthetase induction by hormones in normal and tumorous GR mouse mammary tissue.

Authors:  M Schülein; J L Daehnfeldt; P Briand
Journal:  Int J Cancer       Date:  1974-09-15       Impact factor: 7.396

9.  Oestrogen receptor in human breast cancer tissue and response to endocrine therapy.

Authors:  E Engelsman; J P Persijn; C B Korsten; F J Cleton
Journal:  Br Med J       Date:  1973-06-30

10.  Serum oestradiol-17 beta in normal women.

Authors:  P C England; L G Skinner; K M Cottrell; R A Sellwood
Journal:  Br J Cancer       Date:  1974-06       Impact factor: 7.640

View more
  1 in total

1.  Effect of hormone manipulation on oxidation, reduction and sulphurylation of dehydroepiandrosterone and oestrone in DMBA-induced rat mammary tumours.

Authors:  K Li; D P Chandra; T Pewnim; T Foo; J B Adams
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.